Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + bevacizumab + camrelizumab + pembrolizumab + sintilimab + tislelizumab
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination involves multiple drugs with different mechanisms of action: - **Anlotinib**: A multi-target tyrosine kinase inhibitor targeting VEGFR, PDGFR, FGFR, and c-Kit, primarily used for its anti-angiogenic effects. - **Bevacizumab**: A monoclonal antibody targeting vascular endothelial growth factor (VEGF), used to inhibit angiogenesis. - **Camrelizumab, Pembrolizumab, Sintilimab, and Tislelizumab**: These are checkpoint inhibitors targeting PD-1, enhancing the immune response against cancer cells.
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)ULBP2 (UL16-binding protein 2)VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR (FGFR family)
Beyond the preview
Go deeper on anlotinib + bevacizumab + camrelizumab + pembrolizumab + sintilimab + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + bevacizumab + camrelizumab + pembrolizumab + sintilimab + tislelizumab.